Cargando…

Emerging targets for anticancer vaccination: PD-1

Among the mechanisms by which tumor cells escape the immune surveillance, one is the interaction between programmed cell death protein 1 (PD-1) and its ligand programmed death-ligand 1 (PD-L1). Inhibition of the PD-1/PD-L1 pathway with monoclonal antibodies as immune checkpoint inhibitors targeting...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tobias, J., Steinberger, P., Drinić, M., Wiedermann, U.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517287/ https://www.ncbi.nlm.nih.gov/pubmed/34649221 http://dx.doi.org/10.1016/j.esmoop.2021.100278

Ejemplares similares

Vaccination against Her-2/neu, with focus on peptide-based vaccines
por: Tobias, J., et al.
Publicado: (2022)

Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer
por: Tobias, Joshua, et al.
Publicado: (2022)

Emerging targets for anticancer vaccination: IDH
por: Platten, M., et al.
Publicado: (2021)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

The Emerging Role of IL-9 in the Anticancer Effects of Anti-PD-1 Therapy
por: Vinokurova, Daria, et al.
Publicado: (2023)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
por: Wu, Mengling, et al.
Publicado: (2022)

Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
por: Gong, Jun, et al.
Publicado: (2018)

A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors
por: Tobias, Joshua, et al.
Publicado: (2020)

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities
por: Hack, Stephen P., et al.
Publicado: (2020)

Active immunization with a Her-2/neu-targeting Multi-peptide B cell vaccine prevents lung metastases formation from Her-2/neu breast cancer in a mouse model
por: Tobias, Joshua, et al.
Publicado: (2022)

PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review
por: Planes-Laine, Gabrielle, et al.
Publicado: (2019)

Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
por: Wu, Yuze, et al.
Publicado: (2022)

PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence
por: Tykodi, Scott S
Publicado: (2014)

Therapeutic Emergence of Rhein as a Potential Anticancer Drug: A Review of Its Molecular Targets and Anticancer Properties
por: Henamayee, Sahu, et al.
Publicado: (2020)

Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy
por: Singh, Amit Kumar, et al.
Publicado: (2018)

PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence
por: Tran, Phu N, et al.
Publicado: (2017)

A Biomimetic, Silaffin R5-Based Antigen Delivery Platform
por: Reichinger, Daniela, et al.
Publicado: (2022)

Antioxidant Properties and Aldehyde Reactivity of PD-L1 Targeted Aryl-Pyrazolone Anticancer Agents
por: Leleu-Chavain, Natascha, et al.
Publicado: (2022)

The spliceosome as target for anticancer treatment
por: van Alphen, R J, et al.
Publicado: (2009)

Sphingosine kinase 1 as an anticancer therapeutic target
por: Gao, Ying, et al.
Publicado: (2015)

Oocyst-Derived Extract of Toxoplasma Gondii Serves as Potent Immunomodulator in a Mouse Model of Birch Pollen Allergy
por: Wagner, Angelika, et al.
Publicado: (2016)

Targeting PD-1/PD-L1 in lung cancer: current perspectives
por: González-Cao, María, et al.
Publicado: (2015)

Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma
por: Kammerer-Jacquet, Solène-Florence, et al.
Publicado: (2019)

Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting
por: Baldin, Alexey V., et al.
Publicado: (2020)

Emerging Anticancer Potentials of Selenium on Osteosarcoma
por: Pang, Kok-Lun, et al.
Publicado: (2019)

Dysregulation of protein methyltransferases in human cancer: An emerging target class for anticancer therapy
por: Hamamoto, Ryuji, et al.
Publicado: (2016)

Primary vaccine failure to routine vaccines: Why and what to do?
por: Wiedermann, Ursula, et al.
Publicado: (2016)

Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer
por: Dumitru, Adrian, et al.
Publicado: (2022)

PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells
por: Stecher, Carmen, et al.
Publicado: (2017)

Anti-Tumor Efficacy of Anti-PD-1/PD-L1 Antibodies in Combination With Other Anticancer Drugs in Solid Tumors: A Systematic Review and Meta-Analysis
por: Inoue, Takashi, et al.
Publicado: (2022)

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway
por: Tremblay-LeMay, Rosemarie, et al.
Publicado: (2018)

Emerging role of ubiquitination/deubiquitination modification of PD-1/PD-L1 in cancer immunotherapy
por: Ding, Peng, et al.
Publicado: (2022)

Anticancer Agents Targeted to Sirtuins
por: Kozako, Tomohiro, et al.
Publicado: (2014)

Targeting senescence as an anticancer therapy
por: Bousset, Laura, et al.
Publicado: (2022)

Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy
por: García-Aranda, Marilina, et al.
Publicado: (2019)

Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
por: Yang, Xingcheng, et al.
Publicado: (2022)

Surveilling the Potential for Precision Medicine-driven PD-1/PD-L1-targeted Therapy in HNSCC
por: Mann, JE, et al.
Publicado: (2017)

Emerging Prospects of Nanozymes for Antibacterial and Anticancer Applications
por: Chakraborty, Nayanika, et al.
Publicado: (2022)

PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
por: Khan, Sajid, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ho9edps5kjkgjlngrln0rphsh6